TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6933738

Group type: EXPERIMENTAL
Intervention: 300 mg cyproterone acetate at weekly intervals
Number of subjects: 16

Group type: COMPARATOR
Intervention: 100 mg oestradiol‐17 beta‐undecylate every month
Number of subjects: 16
Study: 6151553

Group type: EXPERIMENTAL
Intervention: Prizidilol hydrochloride (200‐300 mg b.i.d.)
Number of subjects: 13
Study: 31348732

Group type: EXPERIMENTAL
Intervention: Language-specific attention treatment (L-SAT)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Direct attention training (DAT)
Number of subjects: 4
Study: 28772105

Group type: EXPERIMENTAL
Intervention: Commercial sugar-sweetened beverage (SSB) consumption
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sedentary SSB consumption
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 30 minutes of aerobic exercise followed by SSB consumption
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 30 minutes of aerobic exercise followed by water consumption
Number of subjects: 11

Group type: COMPARATOR
Intervention: Water consumption
Number of subjects: 11
Study: 26814620

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) 200U subcutaneous injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 40
Study: 25135738

Group type: EXPERIMENTAL
Intervention: 120 kV tube voltage imaging (Group A)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 100 kV tube voltage imaging (Group B)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 80 kV tube voltage imaging (Group C)
Number of subjects: 300
Study: 22790464

Group type: EXPERIMENTAL
Intervention: Hepatitis C antiviral therapy offered to patients in opioid agonist treatment
Number of subjects: 19
Study: 20962312

Group type: EXPERIMENTAL
Intervention: Fish oil beverage (1.5 g per day for 12 weeks)
Number of subjects: 10
Study: 16761217

Group type: EXPERIMENTAL
Intervention: Tropical climate training for 8 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Altitude training for 8 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Tapering group
Number of subjects: 16
Study: 16225928

Group type: EXPERIMENTAL
Intervention: Early retreatment with verteporfin therapy every 2 months (group A)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard verteporfin therapy every 3 months (group B)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Early retreatment with verteporfin therapy (group A)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard verteporfin therapy (group B)
Number of subjects: 203
Study: 12047482

Group type: EXPERIMENTAL
Intervention: Adalat OROS (fasted state)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Slofedipine XL (fasted state)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Adalat OROS (fed state)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Slofedipine XL (fed state)
Number of subjects: 24
Study: 9933797

Group type: EXPERIMENTAL
Intervention: Tumor cell cultures (CL) from RCC
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Coculture of gamma delta and alpha beta T cell clones with tumor CL
Number of subjects: 27
Study: 7555554

Group type: EXPERIMENTAL
Intervention: Patient empowerment education program (six sessions, one session per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-listed control group (no intervention during the first 6 weeks)
Number of subjects: 0
Study: 2246637

Group type: EXPERIMENTAL
Intervention: 3- to 5-minute unstructured physician discussion encouraging smoking cessation (intervention group)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Comparison group (smokers in practices not involved in delivering the intervention)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: 1-year follow-up (all groups)
Number of subjects: 463
Study: 7398005

Group type: EXPERIMENTAL
Intervention: Partial ileal bypass surgery
Number of subjects: 28
Study: 29666174

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir for 8 weeks
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir with Ribavirin for 8 weeks
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir for 12 weeks
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir with Ribavirin for 12 weeks
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir for 12 weeks (Interferon-experienced)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir with Ribavirin for 12 weeks (Interferon-experienced)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir plus Ribavirin (previously treated with sofosbuvir)
Number of subjects: 255
Study: 29561188

Group type: EXPERIMENTAL
Intervention: Sitagliptin-Metformin (SITA-MET)
Number of subjects: 36
Study: 27218868

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg/d for 1 week and then 30 mg/d for 12 weeks)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 430
Study: 25270432

Group type: EXPERIMENTAL
Intervention: Social activation and physical mobilization program, four times a week for eight weeks
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (non-treated)
Number of subjects: 85
Study: 22283926

Group type: EXPERIMENTAL
Intervention: Histamine-induced itch
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study: 20059593

Group type: EXPERIMENTAL
Intervention: Mandibular infiltration anaesthesia
Number of subjects: 89

Group type: COMPARATOR
Intervention: Mandibular block anaesthesia
Number of subjects: 89
Study: 17379124

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 26
Study: 15589927

Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-drainage
Number of subjects: 200
Study: 12711119

Group type: EXPERIMENTAL
Intervention: Uracil plus Tegafur (UFT) for 2 years (adjuvant group)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Surgical treatment alone (control group)
Number of subjects: 221
Study: 10640160

Group type: EXPERIMENTAL
Intervention: Norplant implant
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Domestic implant
Number of subjects: 61

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 61
Study: 7589771

Group type: EXPERIMENTAL
Intervention: Alpha-glucosidase inhibitor (0.6 mg/day) combined with sulphonylurea (glibenclamide or tolbutamide) for 4 weeks
Number of subjects: 10
Study: 2287705

Group type: EXPERIMENTAL
Intervention: Naloxone administration
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Basal conditions
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Plasma cortisol concentration
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Indicators of dieting (beta-hydroxybutric acid and triiodothyronine)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Height correlations
Number of subjects: 31
Study: 7015536

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of penbutolol (40 mg) and furosemide (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference formulations: Penbutolol capsules (40 mg) and furosemide (20 mg) tablets
Number of subjects: 12
Study: 31342099

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided supraclavicular brachial plexus block
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sedoanalgesia
Number of subjects: 68
Study: 30046804

Group type: EXPERIMENTAL
Intervention: Combined explicit-implicit (E-I) intervention
Number of subjects: 25

Group type: COMPARATOR
Intervention: Implicit-only (I-O) intervention
Number of subjects: 25
Study: 26220329

Group type: EXPERIMENTAL
Intervention: Adaptive physical activity combined with therapeutic patient education (APA-TPE)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 126
Study: 24549525

Group type: EXPERIMENTAL
Intervention: Child Health Initiative for Lifelong Eating and Exercise (CHILE) intervention
Number of subjects: 1879
Study: 22244781

Group type: EXPERIMENTAL
Intervention: hphMG
Number of subjects: 749

Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 749
Study: 19282782

Group type: EXPERIMENTAL
Intervention: ZDV/ddI-based cART
Number of subjects: 650

Group type: COMPARATOR
Intervention: ZDV/3TC or d4T/3TC-based cART
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: NNRTI-based cART
Number of subjects: 650
Study: 17187597

Group type: EXPERIMENTAL
Intervention: Lung recruitment manoeuvre and nasopharyngeal continuous positive airway pressure (CPAP)
Number of subjects: 48
Study: 15878470

Group type: EXPERIMENTAL
Intervention: Weight-loss interventions (behavioral, surgical, pharmacologic)
Number of subjects: 34
Study: 11929440

Group type: EXPERIMENTAL
Intervention: Group therapy programme for adult survivors of child abuse and neglect
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control (waitlist) group
Number of subjects: 83
Study: 9617508

Group type: EXPERIMENTAL
Intervention: Ropinirole (mean daily dose 8.7 mg in early therapy; 8.2 mg in adjunct therapy)
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 1364

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 1364
Study: 8034821

Group type: EXPERIMENTAL
Intervention: Thermal biofeedback with regular home practice (HP)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Thermal biofeedback without home practice (NHP)
Number of subjects: 17
Study: 2656070

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2; 1.4 pmol min‐1 kg‐1; 5 ng min‐1 kg‐1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) during ANG II infusion
Number of subjects: 16

Group type: COMPARATOR
Intervention: ANG II alone
Number of subjects: 16
Study: 31794684

Group type: EXPERIMENTAL
Intervention: VDOT
Number of subjects: 405

Group type: COMPARATOR
Intervention: DOT
Number of subjects: 405
Study: 29547447

Group type: EXPERIMENTAL
Intervention: Aquatic treadmill exercise (ATM)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Land treadmill exercise (LTM)
Number of subjects: 19
Study: 27000764

Group type: EXPERIMENTAL
Intervention: Nonconventional DBS settings (narrow pulse widths, square biphasic pulses, irregular pulse patterns)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Narrow pulse widths
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Square biphasic pulses
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nonconventional settings
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham and clinically-optimal settings
Number of subjects: 11
Study: 24933702

Group type: EXPERIMENTAL
Intervention: Verbalization during encoding (nameability of the stimuli)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postencoding verbalization (verbal descriptions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Final memory task demands (global or featural)
Number of subjects: 0
Study: 22428773

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 19966072

Group type: EXPERIMENTAL
Intervention: VA‐MEDIC intervention (n = 58)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 118
Study: 18490793

Group type: EXPERIMENTAL
Intervention: Positive competence feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 16158373

Group type: EXPERIMENTAL
Intervention: Interval Step (IS)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Continuous Step (CS)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 3
Study: 12865276

Group type: EXPERIMENTAL
Intervention: Endoscopic Balloon Dilatation (EBD)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Endoscopic Sphincterotomy (ES)
Number of subjects: 202
Study: 10370187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 50 microg salbutamol Turbuhaler
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100 microg salbutamol Turbuhaler
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100 microg salbutamol pMDI
Number of subjects: 40
Study: 8848911

Group type: EXPERIMENTAL
Intervention: Balanced analgesia (5 ml of 2% lidocaine gel on the clips and 200 mg of ketoprofen i.v.)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (5 ml of placebo gel on the clips and placebo i.v.)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lidocaine group (5 ml of 2% lidocaine gel on the clips and placebo i.v.)
Number of subjects: 90
Study: 8504578

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (bolus doses of 5 + 5 mmol followed by infusion of 0.04 mmol/min)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Verapamil (5 + 5 mg followed by 0.1 mg/min)
Number of subjects: 57
Study: 3306903

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 30325117

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen cannula (HFNC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional oxygen therapy (COT)
Number of subjects: 100
Study: 26381515

Group type: EXPERIMENTAL
Intervention: Carboplatin-paclitaxel (CP)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both arms (CP and Erlotinib)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Erlotinib (in mucinous tumour patients)
Number of subjects: 130
Study: 23234601

Group type: COMPARATOR
Intervention: pegIFNα‐2a continuing monotherapy (group A, n = 51)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Adefovir (ADV) add‐on therapy (group B, n = 34)
Number of subjects: 85
Study: 21670455

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel
Number of subjects: 1217
Study: 19539117

Group type: EXPERIMENTAL
Intervention: Cervical myofascial induction technique
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham-manual procedure
Number of subjects: 35
Study: 17085752

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity self-efficacy (PASE) measured with 19 items
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Fruit and vegetable self-efficacy (FVSE) measured with 21 items
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: MIRT modeling to assess SocD influences
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Objective measurement of physical activity using CSA/MTI accelerometer
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Food frequency questionnaire for total fruit, juice, and vegetable consumption
Number of subjects: 473
Study: 15261701

Group type: EXPERIMENTAL
Intervention: D2 receptor agonist bromocriptine 3.125 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10680473

Group type: EXPERIMENTAL
Intervention: r-HuEPO (300 IU/kg on day four before surgery and 150 IU/kg daily for the following seven days)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: r-HuEPO
Number of subjects: 81
Study: 8975318

Group type: EXPERIMENTAL
Intervention: Resting 99mTc-MIBI SPECT after nitroglycerine (NTG) administration
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Resting 99mTc-MIBI SPECT delayed images
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Resting delayed and NTG MIBI imaging
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Coronary revascularization (Rev)
Number of subjects: 31
Study: 1757606

Group type: EXPERIMENTAL
Intervention: 0.05% halobetasol propionate ointment
Number of subjects: 104

Group type: COMPARATOR
Intervention: 0.05% betamethasone dipropionate ointment
Number of subjects: 104
Study: 6552999

Group type: EXPERIMENTAL
Intervention: Hexoprenalin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 140
Study: 28819778

Group type: EXPERIMENTAL
Intervention: Jumihaidokuto (6 g daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (antihistamines only)
Number of subjects: 21
Study: 27655039

Group type: EXPERIMENTAL
Intervention: Unguided ICBT (velibra) plus care as usual (CAU)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Unguided ICBT (velibra)
Number of subjects: 139
Study: 25833401

Group type: EXPERIMENTAL
Intervention: Subcutaneous PEG‐IFN‐β1a
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Conventional IFN‐β drugs
Number of subjects: 1500
Study: 21987832

Group type: EXPERIMENTAL
Intervention: Semipermeable membranes applied to skin for the first 7 days of life
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal care (Control Group)
Number of subjects: 42
Study: 21366847

Group type: EXPERIMENTAL
Intervention: Aliskiren/HCTZ 150/12.5 mg
Number of subjects: 451

Group type: COMPARATOR
Intervention: HCTZ 12.5 mg
Number of subjects: 451
Study: 19570341

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 11216

Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 11216
Study: 17127381

Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine (35 microg/h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sustained-release morphine (60 mg/day)
Number of subjects: 0
Study: 15153857

Group type: EXPERIMENTAL
Intervention: Ultraviolet light absorber (UVA) and hindered amine light stabilizer (HALS)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (nonpigmented elastomers)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: UVA and HALS
Number of subjects: 160
Study: 11264125

Group type: EXPERIMENTAL
Intervention: Epithelial flap technique
Number of subjects: 36

Group type: COMPARATOR
Intervention: 20% ethanol debridement
Number of subjects: 36
Study: 9385692

Group type: EXPERIMENTAL
Intervention: Routine epidural corticosteroid injections
Number of subjects: 108

Group type: COMPARATOR
Intervention: Rest and a nonsteroidal antiinflammatory drug
Number of subjects: 108
Study: 8016793

Group type: EXPERIMENTAL
Intervention: Cough
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Forced Expiration Technique (FET)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study: 3142566

Group type: EXPERIMENTAL
Intervention: Test meals containing varying ratios of whole cereal grains (barley or cracked wheat) to milled flour (75:25, 50:50, 0:100)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard white bread control meals
Number of subjects: 16
Study: 4934047

Group type: EXPERIMENTAL
Intervention: Levorphanol 2 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pentazocine 20 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Morphine 10 mg and Cyclizine 50 mg combination
Number of subjects: 13

Group type: COMPARATOR
Intervention: Pethidine 100 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Drug combinations
Number of subjects: 13
Study: 30811543

Group type: EXPERIMENTAL
Intervention: Short 6-week modified tai chi course
Number of subjects: 0
Study: 31519277

Group type: EXPERIMENTAL
Intervention: Dengzhan Shengmai (DZSM) capsules, 0.36 g, twice daily for 12 months
Number of subjects: 3143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3143
Study: 28650791

Group type: EXPERIMENTAL
Intervention: 5% sodium hypochlorite after acid etching for 60 seconds
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Papain gel after acid etching for 60 seconds
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bromelain gel after acid etching for 60 seconds
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (37% phosphoric acid etching for 60 seconds)
Number of subjects: 40
Study: 26332051

Group type: EXPERIMENTAL
Intervention: 16-week shoulder-strength programme with Thera-Band® elastic bands (experimental group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aquatic training (training group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (young sedentary male students)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Concentric action at 3.14 rad s(‐1) (experimental group)
Number of subjects: 40
Study: 24621936

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard CHF therapy (Control)
Number of subjects: 56
Study: 21644059

Group type: EXPERIMENTAL
Intervention: MK‐3134 25 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination of MK‐3134 and Donepezil
Number of subjects: 31

Group type: COMPARATOR
Intervention: Scopolamine 0.5 mg
Number of subjects: 31
Study: 18552277

Group type: EXPERIMENTAL
Intervention: Istradefylline (40 mg daily for 14 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atorvastatin (40 mg single dose)
Number of subjects: 20
Study: 16731138

Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 107

Group type: COMPARATOR
Intervention: On-pump surgery
Number of subjects: 107
Study: 12956494

Group type: EXPERIMENTAL
Intervention: Mandibular two-implant overdentures
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 60
Study: 11139103

Group type: EXPERIMENTAL
Intervention: Fentanyl (8.1 ng/mL)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sufentanil (0.68 ng/mL)
Number of subjects: 21
Study: 9175819

Group type: EXPERIMENTAL
Intervention: HLA-DR-shared blood transfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: HLA-mismatched transfusion
Number of subjects: 0
Study: 8472829

Group type: EXPERIMENTAL
Intervention: 0.8 mg budesonide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2416423

Group type: EXPERIMENTAL
Intervention: Cisplatin + vinblastine + bleomycin
Number of subjects: 191

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 191
Study: 30153096

Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide plus aspirin
Number of subjects: 382

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 382